Antimicrobial resistance became a threat to public health. It constitutes a growing danger to human health in the whole world; but the hospital has always been considered like the most important risk holder (Bradford PA et al. 2001).
Thereby, the first antimicrobial resistance surveillance data published by the World Health Organization (WHO, 2018) showed high levels of resistance to several serious bacterial infections in both high and low income countries. Antimicrobial resistance is responsible for about 700,000 deaths a year worldwide and has huge implications for the cost of healthcare (Jasovsky et al. 2016). The production of Extended-Spectrum β-lactamase (ESBL) by Enterobacteria is the main mechanism of the antimicrobial resistance. Several studies have been conducted on the major genes involved in the production of ESBLs. The most common ESBLs are the Temoneira (TEM), Variable sulfhydryl (SHV) and Cefotaximase-Munich (CTX-M) types (Sadeeq et al. 2018).
The first plasmid TEM-1-type β-lactamase was isolated in 1965 in Greece from a strain of E. coli isolated in a patient named Temoneira hence the name (Zubair et al. 2015). The SHV-types ESBL are derived by punctual mutations from the original SHV-1 enzyme, which corresponds to a K. pneumoniae chromosomal penicillinase blaSHV gene (Brisse and Verhoef 2001; Haeggman et al. 2004). Currently, more than 180 SHV ESBL variants have been described (Liakopoulos et al. 2016). CTX-M ESBLs were initially described in 1986 in Japan, Germany and France in 1989 (CTX-M-1) and have since spread widely around the world (Thomson and Moland 2000). CTX-M is the most prevalent ESBLs worldwide (Paterson et al. 2005).
The CTX-M group (for cefotaximase) originally gave enterobacteria a higher level of resistance to Cefotaxime, Ceftriaxone, Cefepime and Aztreonam than to Ceftazidime (Arlet and Philippon. 2003; Bonnet. 2004). Some of them have evolved more recently by mutation (ponctual or not) generating a high level of resistance to Ceftazidime such as the CTX-M-15, CTX-M-16, CTX-M-19, CTX-M- 23 and CTX-M-32 enzymes (Bonnet. 2004). Recently, more than 150 variants of CTX-M have been described and classified into 6 phylogenetic groups: the CTX-M-1 group; CTX-M-2 and Toho-1 group; the CTX-M-8 group; the CTX-M-9 group, the CTX-M-25 group and finally the CTX-M-45 group. These new ESBLs were not closely related to TEM or SHV β-lactamases since they only showed 40% homology with these classic ESBLs (Elhani. 2012). Horizontal dissemination of the genes coding for the CTX-M enzymes occurs via conjugative plasmids but also via other genetic elements such as integrons and ISEcp1 insertion sequences (Bradford. 2001).
Besides the so-called major ESBLs, there were minor types ESBLs such as TOHO-type, BES-type, Pseudomonas extended Resistance (PER) type, Vietnam extended-spectrum β-lactamase (VEB) type, Guiana extended-spectrum β-lactamase (GES) type, TEM Like Activity (TLA) type, Serratia fonticola (SFO) type which were less studied (Cattoir V, 2008). TOHO-type is a variant of CTX-M2c (Andres et al. 2005). The blaTOHO gene has been described for the first time at Toho University School of Medicine (Japan) in the urine of a one-year-old girl in E. coli TUH12191 (Ishii et al. 1995). This gene has been notified in the first time in Argentina in Shigella flexneri in the stool of a 33-year-old woman (Andres et al. 2005).
TOHO-2 ESBL have also been described as produced by E. coli TUH1083. It was categorized as an enzyme similar to TOHO-1 group β-lactamase rather than to mutants of TEM or SHV enzymes (Ling et al. 1998). The prevalence of the blaTOHO gene in ESBL-producing Enterobacteria has not been reported in the literature yet. Investigations work on β-lactamases at Burkina Faso scale were relatively recent and have already identified the presence of TEM, SHV and CTX-M genes, which are responsible for bacterial resistance in enterobacteria (Zongo et al. 2015).
This study was undertaken with the aim of detecting the blaTOHO gene in ESBLs-producing by Escherichia coli and Klebsiella pneumoniae at Saint Camille Hospital of Ouagadougou (Burkina Faso).